ライフサイエンスコーパス: budesonide

1 a underwent an 8-week treatment with inhaled budesonide.

2 xacerbation rate was reduced by 38.5% versus budesonide.

3 zation, proving a T cell mediated allergy to budesonide.

4 (P= .018) with budesonide/formoterol versus budesonide.

5 ltimately identified, should be treated with budesonide.

6 success with rifaximin, tinidazole, and oral budesonide.

7 eceive placebo or the inhaled corticosteroid budesonide.

8 magnitude as that achieved by treatment with budesonide.

9 , similar in magnitude to that obtained with budesonide.

10 t with B[a]P and similar tumors treated with budesonide.

11 hway and MAPK cascade were also regulated by budesonide.

12 antagonize the effects of dexamethasone and budesonide.

13 significant resistance to chemoprevention by budesonide.

14 flammatory activity to the standard steroid, budesonide.

15 e changes were reduced by the glucocorticoid budesonide.

16 d with IL-17A and/or IL-22, with and without budesonide.

17 sed release of IL-8, even in the presence of budesonide.

18 were enrolled in a 12-week trial of inhaled budesonide.

19 he suppressive effects of the corticosteroid budesonide.

20 Subjects with incident EoE (n = 25) received budesonide 1 mg twice daily, either nebulized and then s

21 They received 7 days of DOICS (budesonide 1,600 mug) and a test for nonadherence based

22 asone (100 nM), dexamethasone (1 microM), or budesonide (100 nM).

23 The effect of budesonide (100 pM to 10 microM) on VEGF secretion, expr

24 cebo (14% fall) (P < 0.05) with no effect of budesonide (12.5% fall) versus placebo (P > 0.05).

25 lar in all groups (43 [88%] of 49 in the TRF-budesonide 16 mg/day group, 48 [94%] of 51 in the TRF-bu

26 INTERPRETATION: TRF-budesonide 16 mg/day, added to optimised RAS blockade, r

27 Overall, at 9 months TRF-budesonide (16 mg/day plus 8 mg/day) was associated with

28 been randomly assigned to receive 400 mug of budesonide, 16 mg of nedocromil, or placebo daily for 4

29 treatment during pregnancy (n = 1231; 79.9% budesonide, 17.6% fluticasone, 5.4% beclomethasone, and

30 50) and the cumulative incidence of relapse (budesonide 20.8% vs. placebo 16.3%, p = 0.547) and non-r

31 HD stage >2 with death as a competing event (budesonide 20.8% vs. placebo 32.6%, p = 0.250) and the c

32 ebulized AZD5423 (75 or 300 mug) once daily, budesonide 200 mug twice daily via Turbuhaler, or placeb

33 eded for asthma symptoms) (albuterol group); budesonide (200 mug, one inhalation through a Turbuhaler

34 16.3%, p = 0.547) and non-relapse mortality (budesonide 28% (95% CI 15-41%) vs. placebo 30% (95% CI 1

35 zed double-blind placebo-controlled trial of budesonide (3 mg/day and 9 mg/day) and prednisolone (7.5

36 re randomised to receive once daily, inhaled budesonide 400 mug (those aged <11 years 200 mug) or pla

37 mmunotherapy; group A (85 patients) received budesonide 400 mug twice daily and group B (40 patients)

38 e 16 mg/day group, 48 [94%] of 51 in the TRF-budesonide 8 mg/day, and 42 [84%] of 50 controls).

39 of three, in a 1:1:1 ratio to 16 mg/day TRF-budesonide, 8 mg/day TRF-budesonide, or placebo, stratif

40 Following treatment, 34% of patients taking budesonide 9 mg and 46% of those taking prednisolone 7.5

41 Oral budesonide (9 mg once daily) is effective and safe for s

42 Oral budesonide, 9 mg daily was administered for 1 year and p

43 Budesonide, a glucocorticoid, was proven to be a highly

44 Cell treatment with the potent GC budesonide accelerated the decay of CCL2 mRNA (t(1/2) =

45 Hjortswang-Criteria, 80.0% of patients given budesonide achieved clinical remission compared with 37.

46 pical budesonide vs 33 of 105 (31.4%) for no budesonide (adjusted odds ratio, 0.93; 95% confidence in

47 However, the efficacy of budesonide against lung tumor progression decreased from

48 the efficacy of the anti-inflammatory agent, budesonide, allowing for prophylactic treatment in a ham

49 as 12.5% (95% CI 3-22%) under treatment with budesonide and 14% (95% CI 4-25%) under placebo (p = 0.8

50 group); or budesonide-formoterol (200 mug of budesonide and 6 mug of formoterol, one inhalation throu

51 ngs show that children with asthma receiving budesonide and beclometasone dipropionate have decreased

52 o permeability of two VEGF inhibitory drugs, budesonide and celecoxib, which are lipophilic and neutr

53 rategy has titrated combination therapy with budesonide and formoterol for both maintenance and relie

54 intenance and reliever (SMART) regimen (with budesonide and formoterol fumarate), and anti-IgE therap

55 bo-controlled, multicenter study to evaluate budesonide and mesalamine as short-term treatments for c

56 e long been needed, and recently two agents, budesonide and mycophenolate mofeteil, show promise in t

57 We further investigated whether budesonide and nedocromil modified pollution effects.

58 Patient improved with increased dose of budesonide and subsequently continued to tolerate usteki

59 mesalamines, and corticosteroids, including budesonide) and complex dosing formulations, regimens, a

60 including dexamethasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signal

61 We found that prednisone, fluticasone, budesonide, and progesterone each increased cAMP levels

62 Infliximab or oral budesonide are helpful in patients with steroid-refracto

63 ithelial cells (pHBECs) using formoterol and budesonide as representative LABA and ICS, respectively.

64 -controlled studies of IL-5 and oral viscous budesonide as well as new large studies examining the sa

65 symptoms were statistically significant with budesonide at 0.25 mg daily (p = 0.040), 0.25 mg twice d

66 olic perturbation, such as the antiasthmatic budesonide, blocked metastatic dissemination of breast c

67 thma (aged>/= 70, n=17) who had treated with budesonide (BUD) 400 mug/day plus Tulo 2 mg/day, were ra

68 ribe interactions between the glucocorticoid budesonide (Bud) and the Smo CRDs from both Drosophila a

69 ned to groups given pH-modified release oral budesonide capsules (9 mg budesonide once daily, Budenof

70 aluated the subgroup of nonsmoking subjects, budesonide caused a significant reduction in nasal condi

71 Treatment with budesonide caused no significant effect on nasal conditi

72 , and 4.02 for mannitol, sodium fluorescein, budesonide, celecoxib, and rhodamine 6G, respectively.

73 pectively, for mannitol, sodium fluorescein, budesonide, celecoxib, and rhodamine 6G.

74 Budesonide, ciclosporin, and rituximab have shown potent

75 om patients with COPD was less responsive to budesonide compared with those from nonsmokers and smoke

76 pression were sensitive to cyclosporin A and budesonide, compounds that inhibit T cell function, sugg

77 TRF-budesonide could become the first specific treatment for

78 ld recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, reduces lung function de

79 ld recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, reduces lung function de

80 rse events were possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplai

81 A549 pulmonary cells, the dexamethasone- and budesonide-dependent repression of interleukin-1beta-ind

82 ne and budesonide, whilst dexamethasone- and budesonide-dependent repression of nuclear factor-kappaB

83 geted-release formulation of budesonide (TRF-budesonide), designed to deliver the drug to the distal

84 f four clinically important corticosteroids (budesonide, dexamethasone, triamcinolone acetonide, and

85 Budesonide did not decrease the occurrence of intestinal

86 The daily regimen of budesonide did not differ significantly from the intermi

87 Budesonide did not reduce allergen-induced sputum eosino

88 Mice treated with budesonide displayed an average of 90% inhibition of lun

89 omethasone-CFC - 548; fluticasone DPI - 445; budesonide DPI - 268; fluticasone-CFC MDI - 111.

90 os (beclomethasone-chlorofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fl

91 tients' ICS treatments to 180 mug or 200 mug budesonide dry powder inhaler twice daily for the entire

92 els, and AHR remained increased with inhaled budesonide during A alternata exposure, but all features

93 he expression profiles of genes modulated by budesonide during murine lung tumorigenesis.

94 which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics

95 Our results suggest that budesonide exerts its effects of chemoprevention through

96 or ulcerative proctosigmoiditis who received budesonide foam 2 mg/25 mL twice daily for 2 weeks, then

97 -controlled trials evaluated the efficacy of budesonide foam for induction of remission in 546 patien

98 tly more frequently among patients receiving budesonide foam than placebo (Study 1: 38.3% vs 25.8%; P

99 tly greater percentage of patients receiving budesonide foam vs placebo achieved rectal bleeding reso

100 ol values were reported more frequently with budesonide foam.

101 ring the effect of treatment with intranasal budesonide for 2 weeks on nasal conditioning.

102 uggested corticosteroid therapies (including budesonide for mild to moderate disease).

103 A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%)

104 e SMART group consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively,

105 tandard group consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively,

106 albuterol (budesonide maintenance group); or budesonide-formoterol (200 mug of budesonide and 6 mug o

107 budesonide was 107+/-109 mug per day in the budesonide-formoterol group and 222+/-113 mug per day in

108 ber of severe exacerbations was lower in the budesonide-formoterol group than in both the albuterol g

109 intenance group (absolute rate, 0.195 in the budesonide-formoterol group vs. 0.175 in the budesonide

110 The annualized exacerbation rate in the budesonide-formoterol group was lower than that in the a

111 inhalation through a Turbuhaler as needed) (budesonide-formoterol group).

112 onist (more than eight actuations per day of budesonide-formoterol in addition to the four maintenanc

113 The Single combination budesonide-formoterol inhaler Maintenance And Reliever T

114 bel trial involving adults with mild asthma, budesonide-formoterol used as needed was superior to alb

115 In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulte

116 that anti-inflammatory reliever therapy with budesonide-formoterol, given on an as-needed basis, is s

117 a 1-month run-in period on low-dose ICS/LABA budesonide/formoterol (BUD/F) 200/6 one inhalation b.i.d

118 manex), (3) montelukast (Singulair), and (4) budesonide/formoterol (Symbicort).

119 desonide/formoterol 400/12 mug twice daily + budesonide/formoterol 200/6 mug as needed for 12 weeks.

120 inhaler) with twice-daily ICS/LABA therapy (budesonide/formoterol 400 mug/12 mug; Turbuhaler).

121 g/d for 2 weeks and maintenance therapy with budesonide/formoterol 400/12 mug twice daily + budesonid

122 Budesonide/formoterol administration led to a significan

123 erbation occurred in 0 and 4 patients in the budesonide/formoterol and budesonide groups, respectivel

124 piratory tract infection (5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively.

125 , the median FEV1 increased by 260 ml in the budesonide/formoterol arm compared with 5 ml in the plac

126 igned either to change control medication to budesonide/formoterol combination (BUD/FM) 320/9 mug/day

127 Twenty-five patients received budesonide/formoterol during the study.

128 Early treatment with inhaled budesonide/formoterol in patients at risk for acute resp

129 pared the efficacy and safety of combination budesonide/formoterol inhaler according to a single inha

130 A large data set from 3 studies comparing budesonide/formoterol maintenance and reliever therapy w

131 The effect of budesonide/formoterol on the FEV1 was maintained in the

132 T recipients with mild/severe BOS to receive budesonide/formoterol or placebo for 6 months.

133 were randomized 1:1 to 320/9 mug twice-daily budesonide/formoterol pMDI or 320 mug twice-daily budeso

134 In this population budesonide/formoterol pMDI was well tolerated over 12 mo

135 t to assess safety and asthma control with a budesonide/formoterol pressurized metered-dose inhaler (

136 (per patient-treatment year) were lower with budesonide/formoterol versus budesonide (incidence, 7.7%

137 sthma exacerbation was longer (P= .018) with budesonide/formoterol versus budesonide.

138 Aerosolized budesonide/formoterol versus placebo bid for up to 5 day

139 initially received placebo were switched to budesonide/formoterol.

140 nd asthma control measures generally favored budesonide/formoterol.

141 established lung adenomas were treated with budesonide, genotype-dependent differential effects of b

142 red in 17% (95% CI 6-28%) of patients in the budesonide group and 19% (CI 7-32%) in the placebo group

143 The reduction in adult height in the budesonide group as compared with the placebo group was

144 st 2 years, decreased growth velocity in the budesonide group occurred primarily in prepubertal parti

145 nfidence interval [CI], -1.9 to -0.5) in the budesonide group than in the placebo group (P=0.001) and

146 a patent ductus arteriosus was lower in the budesonide group than in the placebo group (relative ris

147 bronchopulmonary dysplasia was 27.8% in the budesonide group versus 38.0% in the placebo group (rela

148 A greater percentage of patients in the budesonide group were in clinical remission at week 8 th

149 4 patients in the budesonide/formoterol and budesonide groups, respectively.

150 rcine models was 3H-mannitol > fluorescein > budesonide > celecoxib > rhodamine 6G, with HPbetaCD, an

151 trials with cladibrine, pentoxifylline, and budesonide have failed to demonstrate benefits.

152 inue to demonstrate that steroids, including budesonide, have a greater acute benefit than aminosalic

153 ed the abilities of mesalamine, antibiotics, budesonide, immunomodulators, anti-tumor necrosis factor

154 the effectiveness of amoxicillin and topical budesonide in acute maxillary sinusitis.

155 Budesonide in combination with azathioprine is effective

156 Budesonide in combination with azathioprine is effective

157 in 3 times per day for 7 days and 200 mug of budesonide in each nostril once per day for 10 days.

158 l vs both oral and rectal); (3) role of oral budesonide in patients mild-moderate UC; (4) comparative

159 Our goals were to assess budesonide in patients with treatment-dependent autoimmu

160 Four formulations of albuterol sulfate and budesonide in sieved and milled lactose, respectively, w

161 indicate that the chemopreventive effects of budesonide in the mouse lung tumorigenesis assay involve

162 hase III trial, we evaluated the efficacy of budesonide in the prophylaxis of acute intestinal GvHD a

163 ion, showed much lower systemic effects than budesonide in the thymus involution test, and possessed

164 , genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly rev

165 were lower with budesonide/formoterol versus budesonide (incidence, 7.7% vs 14.0% [P= .006]; rate rat

166 Conversely, budesonide induced 370 and repressed 413 mRNAs, which oc

167 Budesonide-induced hyperglycemia and cosmetic adverse ef

168 trospective analysis suggests that nebulized budesonide inhalation suspension can be administered eff

169 Children were randomly assigned to receive a budesonide inhalation suspension for 1 year as either an

170 At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expr

171 ective for proinflammatory cytokines because budesonide inhibition of LPS-stimulated IL-10 release wa

172 rpose of this study was to determine whether budesonide inhibits expression of vascular endothelial g

173 BACKGROUND & AIMS: Budesonide is a corticosteroid with minimal systemic cor

174 Budesonide is a high-potency, second-generation corticos

175 Budesonide is capable of inhibiting VEGF expression thro

176 Studies reporting that budesonide is effective for the treatment of collagenous

177 Orodispersible budesonide is increasingly prescribed for the treatment

178 alicylates are therapeutic options; however, budesonide is more effective in achieving clinical and h

179 nano- and microparticles produced sustained budesonide levels in the retina and other ocular tissues

180 xposed to budesonide, we engineered MSC with budesonide loaded PLGA microparticles.

181 ve risk, 0.40; 95% CI, 0.18 to 0.86) and the budesonide maintenance group (9 vs. 21; relative risk, 0

182 ot differ significantly from the rate in the budesonide maintenance group (absolute rate, 0.195 in th

183 haler twice daily) plus as-needed albuterol (budesonide maintenance group); or budesonide-formoterol

184 terol group and 222+/-113 mug per day in the budesonide maintenance group.

185 budesonide-formoterol group vs. 0.175 in the budesonide maintenance group; relative rate, 1.12; 95% C

186 ensuring asthma control and non-inferior to budesonide maintenance therapy in preventing exacerbatio

187 nist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA.

188 RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEG

189 MSC efficiently internalized budesonide microparticles and exhibited 4-fold enhanced

190 randomly assigned to groups that were given budesonide MMX (9 mg or 6 mg), mesalamine (2.4 g, as ref

191 Budesonide MMX (9 mg) was safe and more effective than p

192 controlled trial to evaluate the efficacy of budesonide MMX for induction of remission in 509 patient

193 at week 8 among subjects given 9 mg or 6 mg budesonide MMX or mesalamine were 17.9%, 13.2%, and 12.1

194 at week 8 among subjects given 9 mg or 6 mg budesonide MMX or mesalamine were 28.5%, 28.9%, and 25.0

195 at week 8 among patients given 9 mg or 6 mg budesonide MMX or mesalamine were 33.3%, 30.6%, and 33.9

196 at week 8 among subjects given 9 mg or 6 mg budesonide MMX or mesalamine were 41.5%, 35.5%, and 33.1

197 Budesonide MMX(R) is a once-daily oral formulation of bu

198 Gene ontology analysis of the budesonide-modulated transcriptome returned enriched ter

199 in autoimmune hepatitis, and, in contrast to budesonide, mycophenolate mofetil has been effective in

200 ce therapy (n = 15); (2) currently receiving budesonide (n = 10); and (3) currently receiving oral pr

201 nal GvHD until day 100 observed in 91 (n =48 budesonide, n =43 placebo) evaluable patients was 12.5%

202 Of 7138 patients (n=3577 budesonide; n=3561 placebo), baseline symptom frequency

203 rmine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug

204 hort, which was randomly assigned to receive budesonide, nedocromil, or placebo for 4-6 years, we det

205 inant (and potentially beneficial) effect of budesonide on formoterol-induced transcripts, including

206 not negate the positive clinical benefits of budesonide on treating nasal inflammation.

207 though the intermittent-treatment group took budesonide, on average, for only 0.5 week of the year.

208 ified release oral budesonide capsules (9 mg budesonide once daily, Budenofalk, n = 30), mesalamine g

209 g analyses with the major subgroup that used budesonide only, association estimates were of similar m

210 Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression fol

211 odium-induced colitis, the platform carrying budesonide or mesalamine becomes more viscoelastic near

212 ition to daily treatment with either inhaled budesonide or oral zafirlukast over a one-year period.

213 early (within 24 hours after birth) inhaled budesonide or placebo until they no longer required oxyg

214 jects subsequently randomized to either ICS (budesonide) or placebo.

215 hs, the monkeys were treated daily with ICS (budesonide) or saline.

216 cal corticosteroids, such as fluticasone and budesonide, or dietary strategies, such as amino acid-ba

217 re and after 8 wk treatment with formoterol, budesonide, or placebo from atopic asthmatics.

218 io to 16 mg/day TRF-budesonide, 8 mg/day TRF-budesonide, or placebo, stratified by baseline urine pro

219 olled phase 2 trial to assess the ability of budesonide oral suspension (BOS), a novel muco-adherent

220 ial of adults with active EoE, we found that budesonide oral tablets were significantly more effectiv

221 re the efficacy and safety of 2 dosages of a budesonide orodispersible tablet (BOT) vs placebo in mai

222 sess the effectiveness and tolerability of a budesonide orodispersible tablet (BOT), which allows the

223 m a multi-dose inhaler (MDI) or oral viscous budesonide (OVB) slurry, but the 2 have never been compa

224 uate the safety and efficacy of oral viscous budesonide (OVB).

225 essurized metered-dose inhaler (pMDI) versus budesonide over 1 year in African American patients.

226 ter demonstrated a positive response to both budesonide (P = .02) and nedocromil (P = .01) compared w

227 uster demonstrated minimal responses to both budesonide (P = .12) and nedocromil (P = .56) compared w

228 r inhaled corticosteroid exposure (943.5 mug budesonide per day [1502.5] vs 684.3 mug budesonide per

229 mug budesonide per day [1502.5] vs 684.3 mug budesonide per day [390.5], respectively; ratio of means

230 ause of the poor solubility of celecoxib and budesonide, permeability studies were conducted with 5%

231 Budesonide-PLA nano- (345 nm) and microparticles (3.6 mi

232 After subconjunctival administration, both budesonide-PLA nano- and microparticles produced sustain

233 Subconjunctivally administered budesonide-PLA nano- and microparticles sustain retinal

234 Budesonide-PLA nano- and microparticles were administere

235 f budesonide plus formoterol with fixed-dose budesonide plus formoterol and fixed-dose fluticasone pl

236 re over-represented in the genome; moreover, budesonide plus formoterol induced and repressed 609 and

237 ), 2250 asthmatics were randomly assigned to budesonide plus formoterol maintenance and reliever ther

238 Although induction of many mRNAs by budesonide plus formoterol was supra-additive, the domin

239 matics and compared an adjustable regimen of budesonide plus formoterol with fixed-dose budesonide pl

240 maintenance and reliever therapy, fixed-dose budesonide plus formoterol, or fixed-dose fluticasone pl

241 After 2 weeks using a 320 mug twice-daily budesonide pMDI, patients were randomized 1:1 to 320/9 m

242 onide/formoterol pMDI or 320 mug twice-daily budesonide pMDI.

243 ted 4-fold enhanced IDO activity compared to budesonide preconditioned and naive MSC, resulting in a

244 In a lung tumor bioassay, budesonide produced 70% inhibition of tumor multiplicity

245 nhance both gene induction and repression by budesonide provides mechanistic insight as to how adding

246 Mycophenolate mofetil, budesonide, rapamycin, and 6-thioguanine are promising t

247 Mycophenolate mofetil, budesonide, rapamycin, and 6-thioguanine have been effec

248 Budesonide rectal foam was well tolerated and more effic

249 d, phase 3 trials to evaluate the ability of budesonide rectal foam, formulated to optimize retention

250 In vitro fluticasone and budesonide reduced MR1 surface expression twofold and de

251 ency of 65% and 99%, respectively, sustained budesonide release in vitro.

252 oral formulation of budesonide that extends budesonide release throughout the colon using multi-matr

253 5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively.

254 esalamine (RR, 0.67; 95% CrI, 0.39-1.08) nor budesonide (RR, 0.86; 95% CrI, 0.61-1.22), reduced the r

255 rapy (RR, 0.04; 95% CrI, 0.00-0.14), but not budesonide (RR, 0.93; 95% CrI, 0.40-1.84), reduced the r

256 orticoid receptor in the observed effects of budesonide, secretion and mRNA expression studies were a

257 Met772 carriers on budesonide showed a significant improvement in forced ex

258 A 140-gene budesonide signature was identified, of which 48 genes r

259 Budesonide significantly improved stool consistency and

260 Jorveza(R), a newly developed orodispersible budesonide tablet licensed for the treatment of eosinoph

261 al test series as well as the orodispersible budesonide tablet revealed a strong sensitization, provi

262 lower among those who received early inhaled budesonide than among those who received placebo, but th

263 e MMX(R) is a once-daily oral formulation of budesonide that extends budesonide release throughout th

264 s successfully treated with prednisolone and budesonide, the model will be helpful to develop and tes

265 hs, with a safety profile similar to that of budesonide; the asthma exacerbation rate was reduced by

266 therapy or daily zafirlukast therapy, daily budesonide therapy produced greater improvements in pre-

267 t response to topical steroids (oral viscous budesonide), thus offering the potential to inform targe

268 ed trial of AIH treatment to date, comparing budesonide to prednisone.

269 able to show any benefit for the addition of budesonide to standard GvHD prophylaxis.

270 ze retention and provide uniform delivery of budesonide to the rectum and distal colon, to induce rem

271 Budesonide-treated children with asthma had a slight but

272 nificant interaction (P=0.002) was found for budesonide treatment and the AC9 polymorphism.

273 After budesonide treatment there was a significant decrease in

274 ) were modulated back to normal levels after budesonide treatment when compared with the controls gro

275 ms complicated conversion from prednisone to budesonide treatment, and every patient developed at lea

276 mine gene expression changes associated with budesonide treatment.

277 ssed and 120 genes were underexpressed after budesonide treatment.

278 y of a novel targeted-release formulation of budesonide (TRF-budesonide), designed to deliver the dru

279 were randomly assigned to 200 mug of inhaled budesonide twice per day (n = 84) or placebo (n = 56) fo

280 whether there was a differential response to budesonide versus placebo for severe asthma exacerbation

281 For budesonide versus placebo, severe exacerbations requirin

282 For budesonide versus placebo, time to first SARE was longer

283 more days were 32 of 102 (31.4%) for topical budesonide vs 33 of 105 (31.4%) for no budesonide (adjus

284 The mean exposure to budesonide was 104 mg less with the intermittent regimen

285 The mean (+/-SD) dose of inhaled budesonide was 107+/-109 mug per day in the budesonide-f

286 bo-controlled, cross-over study with inhaled budesonide was conducted in 14 subjects with allergic as

287 thy of rigorous study in severe disease, and budesonide was endorsed for study as front-line therapy

288 The chemopreventive efficacy of budesonide was examined in wild-type mice, mice with Ink

289 A daily low-dose regimen of budesonide was not superior to an intermittent high-dose

290 pediatric patients stimulated with IL-33 and budesonide was quantified.

291 mesalamine achieved clinical remission, but budesonide was superior to mesalamine (P = .0035).

292 Although budesonide was tolerated well, we observed a trend towar

293 able when cells were continuously exposed to budesonide, we engineered MSC with budesonide loaded PLG

294 The genomic and non-genomic actions of budesonide were analyzed by RNA-Seq analysis of 24 hours

295 Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleuk

296 ntly, genes regulated by both formoterol and budesonide were over-represented in the genome; moreover

297 de (PLA) nano- and microparticles containing budesonide were prepared by a solvent evaporation techni

298 n a 6 weeks course of topical treatment with budesonide, which needed to be extended due to inadequat

299 ed by RU486 but induced by dexamethasone and budesonide, whilst dexamethasone- and budesonide-depende

300 managed conservatively and treated with oral budesonide with resulting resolution of symptoms.